Tag Archives: Emerging Markets

FDA Finding Fuels Indian Crackdown on Sub-standard Drugs

By Guest Blogger | Published: July 27, 2011
By Mangesh Sai, Asia Correspondent. A routine monthly inspection carried out by the Food and Drugs Administration (FDA) authorities in the state of Maharashtra, India, last month noted an increase in the number of sub-standard drug samples raising apprehensions about the availability of safe and genuine drugs in the state. Officials pointed out that 26 drug samples [...]
Posted in Anti-counterfeiting, Global, Guest Blog, IP, Safety | Also tagged , , , | Leave a comment

Planning Beyond the Petri Dish: A Pfizer Case Study

By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D | Also tagged , , , , , , | Leave a comment

Indian Government Proposes Ban on Physician Gifts

By Ben Comer | Published: June 6, 2011
India’s Department of Pharmaceuticals released a 14-page “voluntary code” for drug marketers, which includes a strict ban on gifts to prescribers, among other things. The code, which is open for public comment until June 30th, states that “no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to persons qualified to prescribe” [...]
Posted in Advertising, Emerging Markets, Global, Marketing, Medical Education, Strategy | Also tagged , , , , , | Leave a comment

Emerging Markets: Looking Beyond the Heady Growth Numbers

By William Looney | Published: April 27, 2011
A sweet helping of “Turkish delight” for local generic producers amounts to harsh medicine for foreign innovator firms… Emerging markets remain the ace in the card deck for big pharma seeking alternatives to the global slowdown in demand for medicines.  The “pharmerging 17” are dealing a strong hand, with a consensus for continued double-digit growth [...]
Posted in Emerging Markets, Europe, Global, R&D | Also tagged , , | Leave a comment

New Decade, New Agenda for Pharma

By Guest Blogger | Published: January 12, 2011
A new track for nonprofits, product diversification and the rise of the emerging markets —  Audrey S. Erbes reports on some of the takeaways from this week’s JP Morgan Healthcare Conference. There were some surprising changes in the format of the 29th Annual JP Morgan Healthcare Conference, the world’s premier health care industry investment meeting which [...]
Posted in Emerging Markets, Guest Blog, R&D | Also tagged , , , , | Leave a comment